This paper explores how mid-size pharmaceutical companies can compete effectively in a landscape dominated by large global players. It highlights structural advantages such as agility, focused portfolios, and faster decision-making, while acknowledging constraints related to scale, resources, and geographic reach. The report outlines strategies for optimizing commercialization, leveraging partnerships, and using data-driven insights to prioritize investments. It also emphasizes the importance of integrated capabilities across R&D, medical, and commercial functions. The paper positions technology, outsourcing, and ecosystem collaboration as key enablers of sustainable growth for mid-size pharma organizations.

Join for free to read